Medical devices, healthcare technology and the business of care
PMA approval · P230042

Optune Lua

Novocure, GmbH · Decision date Oct 15, 2024

FDA DECISIONP230042

What did the FDA approve?

FDA records P230042 as an original PMA application. The recorded decision is approval, dated Oct 15, 2024.

FDA approval order statement

Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
Regulatory pathway
Original PMA
Clinical specialty
Anesthesiology
Decision date
Oct 15, 2024

FDA source record

Regulatory record facts

Identifier
P230042
Regulatory pathway
Premarket approval application
Product code
SDA
Decision code
APPR
Decision date
Oct 15, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.

Product code
SDA
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230042 received

    Application receipt date recorded by FDA.

  2. P230042 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230042

Product / regulatory recordCompanyPathwayDecision dateSource
Optune LuaP230042/S010
Novocure, GmbHPMA supplementOct 26, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records